mifepristone has been researched along with Epithelial Neoplasms in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Baker, GM; Conzen, SD; Fleming, GF; Kocherginsky, M; Lengyel, E; Skor, MN; Stringer-Reasor, EM | 1 |
| Chen, H; Chen, J; Jia, L; Li, T; Liu, J; Liu, W; Wang, J; Zheng, N | 1 |
2 other study(ies) available for mifepristone and Epithelial Neoplasms
| Article | Year |
|---|---|
Glucocorticoid receptor activation inhibits chemotherapy-induced cell death in high-grade serous ovarian carcinoma.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Ovarian Epithelial; Cell Death; Cell Line, Tumor; Cystadenocarcinoma, Serous; Drug Resistance, Neoplasm; Female; Humans; Immunohistochemistry; MCF-7 Cells; Mice; Mice, SCID; Mifepristone; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Random Allocation; Receptors, Glucocorticoid; Xenograft Model Antitumor Assays | 2015 |
Abortifacient metapristone (RU486 derivative) interrupts CXCL12/CXCR4 axis for ovarian metastatic chemoprevention.
Topics: Abortifacient Agents; Animals; Antineoplastic Agents; Carcinoma, Ovarian Epithelial; Cell Adhesion; Cell Line, Tumor; Cell Movement; Cell Proliferation; Chemokine CXCL12; Chemoprevention; Female; Humans; Mice, Inbred BALB C; Mice, Nude; Mifepristone; Neoplasm Invasiveness; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Ovary; Peritoneal Neoplasms; Peritoneum; Receptors, CXCR4; Signal Transduction | 2017 |